Evofem Biosciences Accounts Payable

Evofem Biosciences (EVFM) currently reports a accounts payable of $12M as of March 2026. That compares with $11M in the prior-year period — up 6.9% year over year. Use the charts on this page to explore Evofem Biosciences's accounts payable history and peer comparisons.

Evofem Biosciences's accounts payable increased from $11M to $12M — a 6.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Evofem Biosciences reported $12M in accounts payable as of March 2026. That compares with $11M in the prior-year period — up 6.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $12M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Evofem Biosciences, and consider following EVFM for alerts when major investors trade the stock.

Evofem Biosciences is classified in the Healthcare sector. On accounts payable, it currently shows $12M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EVFM with unrelated industries.